针对阿尔茨海默病的多向药物
Bengisu Turgutalp1, Caghan Kizil2
1Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, Columbia University, 650 West 168th Street, New York, NY 10032, USA; Department of Neurology, Columbia University Irving Medical Center, Columbia University, 710 West 168th Street, New York, NY 10032, USA.
多向药物 (MTD) 通过同时解决多种疾病机制,为阿尔茨海默病 (AD) 治疗提供了一个有希望的方法. 该战略利用新的标和现有化合物,为潜在成功的疾病修饰治疗提供动力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂,多因素的神经退行性疾病,也是痴呆的主要原因.
- 目前的单一向疗法由于AD病理学的复杂性而具有有限的疗效.
- 越来越需要创新的治疗策略来应对AD日益增长的社会和医疗负担.
研究的目的:
- 审查阿尔茨海默病治疗的多向药物 (MTD) 的不断变化的格局.
- 探索MTDs在解决复杂的潜力,多因素性质的AD.
- 突出AD的新遗传洞察力如何为MTD基础疗法的开发提供信息.
主要方法:
- 对有关阿尔茨海默氏症治疗方法的现有文献的综述.
- 分析过去和当前的临床试验,涉及具有多目标活性的化合物.
- 讨论新出现的疾病点和MTD药物设计策略.
主要成果:
- 多向药物方法有可能在阿尔茨海默病中提供协同治疗效果.
- 在现有的化合物基础上,可以加速开发有效的疾病修饰疗法.
- 了解AD遗传学的进展对于识别MTDs的新目标至关重要.
结论:
- 关节疾病代表了阿尔茨海默病的有希望的治疗途径,提供了比单一目标干预更全面的方法.
- MTDs的协同作用有可能在修改AD进展方面取得显著的临床成功.
- 未来的MTDs的发展将受到阿尔茨海默病正在进行的遗传研究的重大影响.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
相关概念视频
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Antidepressant Drugs: MAOIs and Other Agents
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
